At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 222 enrolled
Drug / intervention
TVP-1012 1mgdrug
Likely dose
TVP-1012 1mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Multicenter, Open-label, Long-term, Phase 3 Study to Evaluate the Safety and Efficacy of TVP-1012 at 1 mg in Levodopa Treated Parkinson's Disease Patients
In Brief
A Phase 3 clinical trial evaluating TVP-1012 1mg for Parkinson's Disease. Completed, enrolled 222 participants across 24 sites.
Detailed Summary
The purpose of this study is to evaluate long-term safety of TVP-1012 (1 mg/day) with levodopa in Japanese participants with Parkinson's disease.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsParkinson's Disease
CountriesJapan
Collaborators--
Timeline
Phase 3CompletedFinished
201520162017201820192020202120222023202420252026
First PostedJan 2015
Enrollment StartFeb 2015
Primary CompletionSep 2016
TodayJul 2026
First PostedJan 14, 2015
Enrollment StartFeb 3, 2015
Primary CompletionSep 29, 2016
TodayJul 2, 2026
Enrollment to primary: 1.7 yearsPosted 11.5 years ago
Interventions
TVP-1012 1mgdrug
TVP-1012 1mg Tablets